← Dashboard
Dashboard / Strategy
🎯 Strategy

Brand Strategy & Business Development

The strategic backbone — Brad's playbook (exec summary → SWOT → dermatologist outreach), the evidence-backed SWOT, and the priorities that flow from it. Feeds go-to-market and advisor outreach.

Positioning THE SPINE
"For skin that feels everything."burned — used by 3 brands
Audience line: ⏸ parkedboth leading candidates rejected · brand language resumes later · clearance verdicts + threading criterion banked in Obsidian
For Australians with eczema and reactive skin who are tired of products that feel like medicine, Spanner Skin is sensory-first skincare that makes everyday care fast, calming, and genuinely nice to use — because looking after difficult skin shouldn't feel like a chore or a diagnosis.
ESSENCE: under review  ·  candidates: "Heavy-duty gentleness" · "From the workshop, not the lab" · "Built for difficult skin"
P2 sub-positioning (eyelid): shippable consumer framing — "Purpose-made for the delicate eyelid area — non-steroid, and formulated for comfort on the most reactive skin." (The original "flares your treatment doesn't clear" line survives as internal strategy only — as consumer copy it's a therapeutic claim. Post red-team fix.)
Personas DURABLE ARCHETYPES — PRODUCTS MAP ONTO THEM
Defined by each person's enduring relationship with their skin (severity, mindset, life-role), not by which SKU they buy — so the set holds as the brand expands. 3 core + 1 expansion. Grounded in the 469-item research.
"Jordan" — The Severe / Systemic
Core · medical-maximalist · high LTV
IdentityLifelong severe eczema; on a biologic (Dupixent/Rinvoq); pro-medicine, anti-hype.
RealityBiologic clears the body — face & eyes still flare ("Dupixent eyes"). High medical literacy.
WantsNon-steroid, eye-safe, comfortable relief for what the meds don't reach. Honest complement, never an alternative.
Maps toToday: P2 eye + P1 body · Future: adjuncts across the range
"Maya" — The Moderate Self-Manager
Core · the volume segment
IdentityModerate eczema, no biologic. Tacrolimus + emollients; deliberately steroid-cautious (TSW/thinning).
Key tensionTacrolimus is eye-safe — but burns like hell. Adherence suffers. The greasing grind.
WantsNon-steroid, non-burning soothing she can use anywhere; a routine that's bearable and dignified.
Maps toToday: P1 body + P2 eye · Future: core buyer of most SKUs
"Sam" — The Sensitive / Lifestyle
Growth · non-clinical · brand-led
IdentitySensitive/reactive skin (not clinical). Barrier-care enthusiast; skin as self-care, not burden.
RealityRides the K-beauty wave; values aesthetics AND ingredients. TikTok / Mecca / Adore.
WantsBarrier care that's effective and beautiful, from a brand with a story.
Maps toToday: P1 + gateway · Future: adjacent categories
"Hannah" — The Caregiver
Expansion (future) · not the user, the decision-maker
IdentityParent of a child with eczema. Emotionally charged, high-stakes, research-obsessed.
RealitySleepless nights, scratching child, amplified steroid fear (won't use strong steroids on a baby).
WantsSomething safe, gentle, trustworthy. Reassurance as much as product.
Maps toToday: not served (adult products) · Future: baby / kids / family line
Sharpest product insight: the two clinical archetypes (Jordan, Maya) both converge on the eye area, where the unmet need is non-steroid + non-burning. Steroids are comfortable but unsafe near eyes; tacrolimus is eye-safe but stings. P2 owns the space between them.
Brand Aperture ECZEMA NOW → SENSITIVE LATER
Beachhead strategy: own the hardest customer first (eczema), then widen. Sharp tip, broad base — products map onto the rings, the aperture opens outward over time.
Expansion (future)
Hannah — Caregiver → baby/kids/family
Halo — sensitive/reactive
Sam — the "Tower 28" audience
Core — eczema
Jordan · Maya
"If it's gentle enough for eczema, it's gentle enough for anyone with sensitive skin."
Eczema-specificity isn't a ceiling — it's the proof point that earns the broad audience. Win the hardest case; the wider sensitive-skin market trusts you because of it.
The name helps: "Spanner Skin" (not Beauty) is an open-ended umbrella — eczema → sensitive → skin-health, never boxed into makeup. A wider runway than Tower 28 Beauty.
Guardrail: don't widen too fast — generic "sensitive" won't hold a premium. Sequence: own eczema → earn authority → widen deliberately.
Brad's Playbook THE 3-STEP SPINE
Talia's dad Brad's repeatable method for validating a business via expert advisors before launch. Goal: complete all three within ~3 months.
STEP 1
Executive Summary
One-page business summary used to introduce Spanner Skin to dermatologist advisors.
Not started
STEP 2
SWOT Analysis
Evidence-backed strengths, weaknesses, opportunities, threats — see below.
✓ Done
STEP 3
Dermatologist Outreach
Email top 3–5 women dermatologists (Melbourne/Sydney) for advice — not a pitch, not money. Vanessa Morgan already a connection.
Not started
SWOT EVIDENCE-BACKED
Built on the competitor sweep (27 brands), the 469-item community research, and the BOV market-gap analysis.
💪 Strengths
  • Authentic founder–market fit — lifelong eczema, on Dupixent. The exact derm-outreach hook.
  • First-mover on premium BOV spray for eczema in AU — only Curél/Aquaphor occupy it, neither premium-AU.
  • Format solves named pain — no-touch spray answers "greasing" friction + "burns on broken skin".
  • Ownable brand identity — owns desirability, which no AU eczema brand does.
  • Validated P2 (eyelid) — 7× confirmed gap + the biologics buyer.
  • Evidence engine + relevant day job (Adore Beauty, tech/SEO).
⚠ Weaknesses
  • Pre-everything — pre-revenue, pre-formulation, solo, alongside a job.
  • No in-house formulation — BOV is complex + expensive to produce.
  • Capital constraints — tooling, MOQs, EAA cert all cost money.
  • Zero awareness — social handles not yet secured.
  • Cosmetic claim limits — can't say "treats/heals" (what sufferers search).
  • No derm advisor yet — credibility gap (Brad's step 3 pending).
🚀 Opportunities
  • Open AU lane — no beloved AU eczema brand; Dermeze failing; people repurpose Bepanthen.
  • P2 + biologics wave — Dupixent crowd clears body, battles face/eye, wants non-steroid topical.
  • K/J-beauty body-care wave reaching AU — proves appetite, availability gap.
  • Proven prestige retail paths — Nécessaire/Tower 28 (Sephora), Bangn Body (Mecca); Adore is Talia's channel.
  • Cheap community trust + derm advisor network (Vanessa Morgan).
  • EAA certification as a launch trust anchor.
🛡 Threats
  • Entrenched incumbents — QV/MooGoo/Ego cheap + trusted; CeraVe is derm default.
  • Well-funded entrants — Nécessaire/Curél/Aquaphor could take the BOV gap.
  • BOV supply-chain risk — few AU aerosol makers, high MOQs, propellant rules.
  • Regulatory drift — ACCC claims crackdown / TGA reclassification risk.
  • High trust bar — sufferers burned by hype; price compression from pharmacy dupes.
  • Derms may have own product lines — possible conflict.
Red Team Stress-Test 6 JUL 2026 — TRIED TO BREAK IT
Adversarial review of the whole foundation before derm outreach. Four critical cracks found — none fatal, all fixable. Full report in the vault.
🔴 Critical — fix before derm outreach
  • "Eczema" is a regulated word. Cosmetics can only say "eczema-prone skin" — AU incumbents saying "eczema" on pack hold AUST L listings. Claims architecture needed (EAA seal, copy discipline, maybe AUST L later). Perfect advisor question for the derms.
  • The biologics wedge is small in AU absolute numbers (low tens of thousands). Reframe: Jordan = beachhead & megaphone; Maya's broader eye-area population = the actual P2 market.
  • White space is narrower than framed. Hypochlorous sprays (Tower 28 SOS), thermal mists & Curél already serve the "no-touch spray" job. Fix (Talia's call): two angles, both kept — experience-led (the spritz/no-touch feel) for brand moments, outcome-led ("moisture that stays") for comparative moments. Only hard rule: never headline the jargon "BOV".
  • BOV economics still unexamined. MOQs, few AU fillers, viscosity feasibility. One manufacturer quote gates the P1-vs-P2 call. Cheap intel — get it.
✅ What survives (the important stuff)
  • Founder–market fit — unassailable, unreplicable.
  • The sensory insight ("feels everything", no-touch, dignity) — real, differentiated, and regulation-proof: you can always own how it feels.
  • The eye-area gap (non-steroid + non-burning) — survives the TAM haircut; Maya's population carries it.
  • The desirability gap in AU + the aperture logic — the regulatory constraint actually reinforces "eczema-prone/reactive" as both the legal phrasing and the wider market.
  • The name — no claims, no ceiling.
Serious (fix soon): research skews US/severe — thin AU data · "non-stinging" can't be promised as an absolute · premium price untested vs community price sensitivity · scope creep — the P1-vs-P2 call is the scope-control mechanism, not polish.
Strategic Priorities WHAT THE SWOT TELLS US TO DO
Cross-linking the quadrants turns the lists into action.
1
Use the founder story + derm advisors to beat the trust/awareness weakness. Talia's authentic eczema/Dupixent story + a named dermatologist advisor counter "no awareness" and "no credibility." Execute Brad's outreach next. S→W, O
2
Lead with P2 (eyelid) to the biologics community. Most-validated gap meets the most motivated, underserved, higher-income buyer. A defensible wedge big players ignore. S×O
3
Make format + brand the moat, not ingredients. Incumbents and dupes win on price/parity; Spanner Skin wins on BOV experience + desirability. Don't compete on cheapness. S vs T
4
De-risk the BOV supply chain early. The biggest execution risk — validate AU/contract BOV manufacturers + MOQs before over-committing to brand build. W×T
5
Build community equity now, cheaply — claims-free. An honest, genuinely-helpful Reddit/TikTok presence pre-launch converts the cheap-trust opportunity. Never "miracle"/anti-medicine framing. ⚠️ Guardrail (verified TGA guidance): attaching product claims to condition-community placements can convert them to therapeutic — in eczema communities, be helpful as people, never as product ads. O
6
Pursue EAA certification as the trust anchor. Neutralises the incumbent trust advantage at launch. O vs T